AstraZeneca Revitalizes Crestor With Atherosclerosis Ad Campaign
This article was originally published in The Pink Sheet Daily
Executive Summary
Company makes hay from Merck/Schering-Plough's failed Vytorin atherosclerosis trial.
You may also be interested in...
AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development
Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.
AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development
Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.
AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.